VIDEO: Collagenase injection effective in Dupuytren’s disease with varied severity

ByGary M. Pess, MD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

In this video from the American Society for Surgery of the Hand Annual Meeting, Gary M. Pess, MD, FACS, FAAOS, discusses a Delphi method to assess collagenase clostridium histolyticum use among hand surgeons who treat Dupuytren’s disease.

Researchers used online surveys to determine whether consensus could be reached among 20 hand surgeons with expertise in Dupuytren’s disease (DD) regarding XIAFLEX (Endo International) collagenase clostridium histolyticum as a nonsurgical option for DD. They captured the responses using a five-point Likert scale.

“To my surprise and most of the panelists, we found that people were using XIAFLEX for a variety of contractures, including severe contractures of the [metacarpal] MP and [proximal interphalangeal] PIP joint, even patients with very limited skin and PIP joint capsular contractures,” Pess told Healio Orthopedics.